The short version of MC4R agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-16 and is reviewed periodically as new material appears.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Since 28 February 2026, the United States and Israel have been at war with Iran and its regional allies. The war follows the Twelve-Day War in June 2025 and sporadic fighting during the Middle Eastern crisis sparked by the Gaza war (2023–present). Amid ongoing US–Iran negotiations regarding Iran's nuclear program, the war began when the US and Israel conducted hundreds of air strikes on targets across Iran, including strikes that assassinated Supreme Leader Ali Khamenei alongside several other Iranian officials. American rationale for initiating the war included regime change, preventing Iran from obtaining a nuclear weapon, a response to the massacre of several if not tens of thousands of anti-government protesters in Iran, and taking Iran's oil and gas resources. Critics have rejected these justifications, maintaining that the attack initiated a war of aggression, in violation of international law. Later war goals focused on nuclear negotiations and reopening the Strait of Hormuz. Public opinion was opposed to the war in the United States and in many other countries, leading to widespread disapproval for Donald Trump and declining views of the US and Israel around the world. The war was preceded in January–February 2026 by the largest US military buildup in the region since the 2003 invasion of Iraq.
== Blood for Britain == In late 1940, before the U.S. entered World War II and just after earning his doctorate, Drew was recruited by John Scudder to help set up and administer an early prototype program for blood storage and preservation. Here Drew applied his thesis research to aid in blood preservation and transportation. He collected, tested, and transported large quantities of blood plasma for distribution in the United Kingdom. Drew understood that plasma extraction from blood required both centrifugation and liquid extraction. Each extraction was conducted under controlled conditions to eliminate risk of contamination. Air concealment, ultraviolet light, and Merthiolate were all used to mitigate the possibility of plasma contamination.
The term poison is often used colloquially to describe any harmful substance, especially corrosive substances, carcinogens, mutagens, teratogens, and harmful pollutants. In everyday language, it is sometimes used to exaggerate the perceived danger of certain chemicals. The 16th-century physician Paracelsus (1493–1541), regarded as the father of toxicology, famously stated: "Everything is poison, there is poison in everything. Only the dose makes a thing not a poison." (See: LD50). The term is also used in a figurative sense—for example: "His brother's presence poisoned the atmosphere at the party." In contrast, legal definitions of "poison" tend to be narrower. Some substances that are not legally required to carry a "poison" label may still cause medical conditions associated with poisoning. Some poisons are also classified as toxins, which are toxic substances produced by living organisms. Examples include bacterial proteins responsible for conditions such as tetanus and botulism. While a distinction exists between "poison" and "toxin", the terms are often used interchangeably, even in scientific contexts. Related adjectives include toxic and poisonous, which are generally considered synonymous. Poisonous substances introduced into the body by sting or bite are known as venoms. In everyday usage, a poisonous organism is one that causes harm when ingested or touched, while a venomous organism uses venom actively to incapacitate prey or deter predators. Although rare, some organisms may be both poisonous and venomous.
== Moscow rings == Moscow's road system is approximately centered around the Kremlin at the city's core. From there, roads generally radiate outward to intersect with a series of circular roads ("rings"):
Sources: en.wikipedia.org
=== Somalia === In Somalia, frankincense is harvested in the Bari and Sanaag regions: mountains lying at the northwest of Erigavo; El Afweyn District; Cal Madow mountain range, a westerly escarpment that runs parallel to the coast; Cal Miskeed, including Hantaara and Habeeno plateau and a middle segment of the frankincense-growing escarpment; Karkaar mountains or eastern escarpment, which lies at the eastern fringe of the frankincense escarpment.
== Usage == Young's modulus enables the calculation of the change in the dimension of a bar made of an isotropic elastic material under tensile or compressive loads. For instance, it predicts how much a material sample extends under tension or shortens under compression. The Young's modulus directly applies to cases of uniaxial stress; that is, tensile or compressive stress in one direction and no stress in the other directions. Young's modulus is also used in order to predict the deflection that will occur in a statically determinate beam when a load is applied at a point in between the beam's supports. Other elastic calculations usually require the use of one additional elastic property, such as the shear modulus
Having lost 20 million people in the war, suffered German invasion twice in 30 years, and suffered tens of millions of casualties from onslaughts from the West three times in the preceding 150 years, the Soviet Union was determined to destroy Germany's capacity for another war. This was in alignment with the Allied policy which had foreseen returning Germany to a pastoral state without heavy industry (the Morgenthau Plan). On September 6, 1946, US Secretary of State James F. Byrnes made a speech in Germany, repudiating the Morgenthau Plan and warning the Soviets that the US intended to maintain a military presence in Europe indefinitely. (see Restatement of Policy on Germany) As Byrnes admitted one month later, "The nub of our program was to win the German people [...] it was a battle between us and Russia over minds ...". Because of the increasing costs of food imports to avoid mass-starvation in Germany, and with the danger of losing the entire nation to communism, the US government abandoned the Morgenthau plan in September 1946 with Secretary of State James F. Byrnes's speech Restatement of Policy on Germany. In January 1947, Truman appointed General George Marshall as Secretary of State, scrapped Joint Chiefs of Staff (JCS) directive 1067, which embodied the Morgenthau Plan and supplanted it with JCS 1779, which decreed that an orderly and prosperous Europe requires the economic contributions of a stable and productive Germany".
=== Biological characteristics === Its rapid growth and its ability to reproduce from buried rhizomes and tubers facilitates the Jerusalem artichoke's uncontrolled spread. The vegetative propagules can be transported via rivers and water streams and begin a new population on riverbanks. Dispersal by animal is also possible, as animals feed on tubers and rhizomes and excrete the propagules in new areas. With humans' cultivation, there is also a risk of the plant's unintended escape into the wild. It can also be propagated by seed. Its relatively long flower period enables the Jerusalem artichoke to increase its reproductive potential.
In June 2023, Starbucks attracted controversy for allegedly not allowing workers at some locations in 22 states to put up Pride Month decorations. It came during an ongoing public furor over the direction of LGBTQ+ rights in the US, with other major corporations, like Target and AB-InBev, which manufactures Bud Light, also receiving heightened criticism and scrutiny. A strike at some stores was announced as a result.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.